Dora Dias‐Santagata

21.8k total citations · 3 hit papers
112 papers, 7.8k citations indexed

About

Dora Dias‐Santagata is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dora Dias‐Santagata has authored 112 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Dora Dias‐Santagata's work include Lung Cancer Treatments and Mutations (24 papers), Cancer Genomics and Diagnostics (22 papers) and Genetic factors in colorectal cancer (14 papers). Dora Dias‐Santagata is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Cancer Genomics and Diagnostics (22 papers) and Genetic factors in colorectal cancer (14 papers). Dora Dias‐Santagata collaborates with scholars based in United States, Japan and Canada. Dora Dias‐Santagata's co-authors include A. John Iafrate, Jeffrey A. Engelman, Darrell R. Borger, Jeffrey Settleman, Mari Mino–Kenudson, Mel Β. Feany, Peter M. Sadow, Ryan B. Corcoran, Tudor A. Fulga and Leif W. Ellisen and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Dora Dias‐Santagata

106 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

2012 767 citations Ryan B. Corcoran, Hiromichi Ebi et al. Cancer Discovery profile →
Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

2011 548 citations Darrell R. Borger, David P. Ryan et al. profile →
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

2013 460 citations Amanda C. Pawlak, Mari Mino–Kenudson et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dora Dias‐Santagata United States	44	3.5k	3.2k	2.2k	1.6k	1.2k	112	7.8k
Shikha Bose United States	43	2.6k 0.8×	6.3k 1.9×	1.1k 0.5×	2.1k 1.3×	1.6k 1.3×	109	10.2k
Jordi Rodón United States	48	4.1k 1.2×	5.8k 1.8×	2.4k 1.1×	2.3k 1.4×	1.2k 1.0×	402	10.2k
Ludovic Lacroix France	47	2.7k 0.8×	2.7k 0.8×	2.3k 1.0×	2.0k 1.2×	643 0.5×	220	7.5k
Barry S. Taylor United States	46	3.3k 1.0×	5.5k 1.7×	2.7k 1.2×	3.0k 1.9×	1.4k 1.2×	118	9.9k
Juha Kononen Finland	43	4.8k 1.4×	8.0k 2.5×	2.6k 1.2×	2.8k 1.7×	1.1k 0.9×	83	13.5k
Yoon‐La Choi South Korea	51	3.9k 1.1×	2.8k 0.9×	4.0k 1.8×	2.0k 1.2×	833 0.7×	288	8.3k
Livio Trusolino Italy	51	4.4k 1.3×	4.9k 1.5×	1.7k 0.8×	2.2k 1.4×	1.3k 1.1×	135	10.2k
Peter Schraml Switzerland	53	4.5k 1.3×	7.4k 2.3×	3.3k 1.5×	3.5k 2.2×	977 0.8×	158	12.1k
Robert L. Camp United States	56	5.7k 1.6×	6.2k 1.9×	2.3k 1.1×	2.4k 1.5×	1.0k 0.8×	118	12.8k
Kelli Montgomery United States	43	2.1k 0.6×	3.3k 1.0×	2.4k 1.1×	1.6k 1.0×	824 0.7×	64	7.6k

Countries citing papers authored by Dora Dias‐Santagata

Since Specialization

Citations

This map shows the geographic impact of Dora Dias‐Santagata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dora Dias‐Santagata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dora Dias‐Santagata more than expected).

Fields of papers citing papers by Dora Dias‐Santagata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dora Dias‐Santagata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dora Dias‐Santagata. The network helps show where Dora Dias‐Santagata may publish in the future.

Co-authorship network of co-authors of Dora Dias‐Santagata

This figure shows the co-authorship network connecting the top 25 collaborators of Dora Dias‐Santagata. A scholar is included among the top collaborators of Dora Dias‐Santagata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dora Dias‐Santagata. Dora Dias‐Santagata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pettersson, Maria, Dora Dias‐Santagata, Daniel Nilsson, et al.. (2023). Case report: Extending the spectrum of clinical and molecular findings in FOXC1 haploinsufficiency syndrome. Frontiers in Genetics. 14. 1174046–1174046. 5 indexed citations

Guilmette, Julie, Dora Dias‐Santagata, Jochen K. Lennerz, et al.. (2022). Primary Thyroid Neoplasm with Fetal Morphology Associated with DICER1 Mutations: Expanding the Diagnostic Profile of Thyroblastoma. Thyroid. 32(11). 1423–1428. 9 indexed citations

Le, Long P., Valentina Nardi, Alexander Farahani, et al.. (2022). Identification of fusions with potential clinical significance in melanoma. Modern Pathology. 35(12). 1837–1847. 18 indexed citations

Wróblewska, Joanna, Dora Dias‐Santagata, Masakazu Fujimoto, et al.. (2021). Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas. Cells. 10(9). 2216–2216. 13 indexed citations

Donizy, Piotr, Joanna Wróblewska, Dora Dias‐Santagata, et al.. (2021). Merkel Cell Carcinoma of Unknown Primary: Immunohistochemical and Molecular Analyses Reveal Distinct UV-Signature/MCPyV-Negative and High Immunogenicity/MCPyV-Positive Profiles. Cancers. 13(7). 1621–1621. 12 indexed citations

Dias‐Santagata, Dora, Jochen K. Lennerz, Peter M. Sadow, et al.. (2020). Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid. 30(9). 1384–1389. 33 indexed citations

Fingeret, Abbey, et al.. (2020). BRAF ^V600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence. World Journal of Surgery. 44(8). 2685–2691. 27 indexed citations

Chu, Ying‐Hsia, Dora Dias‐Santagata, Alexander Farahani, et al.. (2020). Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Modern Pathology. 33(11). 2186–2197. 78 indexed citations

Chu, Ying‐Hsia, Lori J. Wirth, Alexander Farahani, et al.. (2020). Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Modern Pathology. 33(12). 2458–2472. 76 indexed citations

10.

Krane, Jeffrey F., et al.. (2017). Primary Benign and Malignant Thyroid Neoplasms With Signet Ring Cells. American Journal of Clinical Pathology. 148(3). 251–258. 13 indexed citations

11.

Wakimoto, Hiroaki, Shota Tanaka, William T. Curry, et al.. (2014). Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas. Clinical Cancer Research. 20(11). 2898–2909. 130 indexed citations

12.

Lubitz, Carrie C., Konstantinos P. Economopoulos, Amanda C. Pawlak, et al.. (2014). Hobnail Variant of Papillary Thyroid Carcinoma: An Institutional Case Series and Molecular Profile. Thyroid. 24(6). 958–965. 72 indexed citations

13.

Tse, Julie Y., et al.. (2012). Basal Cell Carcinoma With Osteosarcomatous Component. American Journal of Dermatopathology. 35(2). 261–265. 7 indexed citations

14.

Corcoran, Ryan B., Hiromichi Ebi, Alexa B. Turke, et al.. (2012). EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discovery. 2(3). 227–235. 767 indexed citations breakdown →

15.

Louissaint, Abner, Adam Ackerman, Dora Dias‐Santagata, et al.. (2012). Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 120(12). 2395–2404. 89 indexed citations

16.

Nardi, Valentina, Youngchul Song, Juan A. Santamaria‐Barria, et al.. (2012). Activation of PI3K Signaling in Merkel Cell Carcinoma. Clinical Cancer Research. 18(5). 1227–1236. 87 indexed citations

17.

Le, Long P., Dora Dias‐Santagata, Amanda C. Pawlak, et al.. (2012). Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses. PLoS ONE. 7(10). e47290–e47290. 37 indexed citations

18.

Montagut, Clara, Sreenath V. Sharma, Toshi Shioda, et al.. (2008). Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. Cancer Research. 68(12). 4853–4861. 405 indexed citations

19.

Xu, Xinsong, Antonio Sarikas, Dora Dias‐Santagata, et al.. (2008). The CUL7 E3 Ubiquitin Ligase Targets Insulin Receptor Substrate 1 for Ubiquitin-Dependent Degradation. Molecular Cell. 30(4). 403–414. 178 indexed citations

20.

Dowell, Joshua D., Shih-Chong Tsai, Dora Dias‐Santagata, et al.. (2006). Expression of a mutant p193/CUL7 molecule confers resistance to MG132- and etoposide-induced apoptosis independent of p53 or Parc binding. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1773(3). 358–366. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact